Your drug discovery partner

idealp Pharma

From biol
to first-in

About Idealp-pharma

Idealp-Pharma has a long track record of partnerships with start-ups, biotechs firms and mid & big pharma companies in a broad range of therapeutic areas.

By applying its medicinal chemistry expertise, its innovative cheminformatics approach and its key capabilities in screening, ADMET & preclinical development, Idealp-Pharma is an ideal partner for providing a fully integrated drug discovery service from the identification of your biological target through to first-in-man use.

Idealp-Pharma provides also stand-alone services in chemistry, medicinal chemistry and cheminformatics to complement and support your in-house resources. Chemists, biologists and computational chemists work closely together to speed up your hit discovery, hit-to-lead and lead-to-candidate phases considering drug discovery as an art creation process…

ogical target
-man use

Searching and picking up validated hits from a compound collection

Hit identification and validation

Idealp-Pharma **designs focused and general drug-like libraries** starting from a highly diverse collection of commercial compounds. We evaluate molecular diversity in terms of scaffolds and not just computed descriptors. We cluster, dock, screen and pick up hits for your target, on the basis of either a known pharmacophore or the active site's 3D structure.

Idealp Pharma masters the **synthesis of selected chemical libraries,** standard multistep and parallel synthesis and purification & analysis, with expertise in devising novel synthetic routes for molecules of interest in a broad range of therapeutic areas and compound classes.

We can assess a compound's activity in **primary screening** (including test design and set-up), evaluate **chemical space** and synthesize analogues for patent expansion & protection, measure pKa values and assess aqueous solubility & chemical stability.

Our biology capabilities enable us to rapidly assess solubility in medium and culture buffer and generate an initial profile of a molecule's **physical-chemical properties.**

Accelerating lead optimization

Hit-to-lead progression

Idealp-Pharma can design combinatorial **virtual libraries** based on the scaffolds, linkers and functional groups of interest. Our SLF Libmaker is a powerful tool for speeding up the lead optimization process, in combination with **docking**- and **pharmacophore-based** approaches.

In each project, computational scientists, biologists and chemists work together in order to optimize the **choice of building blocks, hit ranking, synthetic accessibility** and SAR studies. Our medicinal chemists are experienced in **building SARs** and **optimizing ADMET properties** on the basis of primary and secondary screening results.

Idealp-Pharma performs on-site, exploratory in vitro ADMET **permeability** assays, **metabolic & plasma stability** tests and **CYP 450 inhibition** and **cytotoxicity** tests on hits, in order to give test compounds the best possible chances of being bioavailable in vivo. Raw experimental data are always available for discussion with our clients and **synthesis programmes** can be refocused at any time. You can then **make the best decision** for the lead optimization process, according to your specifications.

Identifying IND candidates



Lead-to-candidate progression

Our scientists **refine SARs** against previously generated data and following discussion with our biologists and computational chemists. Idealp-Pharma can also **synthesize metabolites** and monitor their activity.

Drug selectivity and secondary target identification can be checked by inverse virtual screening. *In silico* ligand profiling helps address potency and selectivity issues and thus anticipates pharmacological side effects.

The ***in vivo* bioavailability** and toxicity of the most promising lead compounds can be assessed well upstream in the drug discovery process, in order to confirm previous in vitro ADMET results.

Idealp-Pharma can manage its customers' **preclinical development** projects because drug discovery, optimization and development are all linked. We help our customers to complete their requirements for **INDs** and **IMPDs**: preliminary formulation, scale-up, toxicology studies, CMC, safety pharmacology and genotoxicity.

Inspiration first & open minded team

Our strengths

- A one-stop shop, from the biological target to first-in-man use
- Stand-alone services to complement your in-house resources
- Good communication and direct, on-line access to all project data
- A flexible working approach

Support for emerging projects

- Support for business plan and report writing
- Advise on scientific and IP strategies for start-ups
- Your outsourced drug discovery department
- Medicinal chemistry expertise

Idealp-Pharma has won the confidence of many well-known companies, including :

- Addex Pharmaceuticals,
- Anaconda Pharma,
- Bayer,
- Cellvir,
- Cytomics Pharmaceuticals,
- E.O.S.,
- Exonhit Therapeutics,
- Faust Pharmaceuticals,
- Fournier Pharma,
- GlaxoSmithKline,
- Galapagos,
- Guerbet,
- Institut Lejeune,
- Laboratoires Pierre Fabre,
- Merck KGaA,
- Mutabilis,
- Nicox,
- Obetherapy,
- Sanofi-Synthelabo,
- Sepal Pharma,
- Servier,
- Solvay,
- Texinfine,
- Theraptosis,
- Trophos,
- Urogene,
- Vivalis,
- the Zambon Group
- ....

Idealp-Pharma

66, boulevard Niels Bohr - Bâtiment CEI - BP 52132
69603 VILLEURBANNE cedex FRANCE
Tel: +33 437 48 88 02 - Fax: +33 478 93 56 53
E-mail : info@idealp.com
Web : www.idealp-pharma.com